Hepato-/reno-protective activity of Chinese prescription Kangen-karyu through inhibition of AGE formation and fibrosis-related protein expression in type 2 diabetes

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 7, 2011, Pages 952-959

  Okamoto, Takuya ^a,b,c   Park, Chan Hum ^a   Noh, Jeong Sook ^a   Toriizuka, Kazuo ^c   Sei, Yasuo ^b   Park, Jong Cheol ^d   Yokozawa, Takako ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Iskra Industry Co Ltd   (Japan)

^c SHOWA UNIVERSITY   (Japan)

^d Sunchon National University   (South Korea)

Author keywords

AGE; db db mice; fibrosis; Kangen karyu; type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CHINESE DRUG; COLLAGEN TYPE 4; CREATININE; FIBRONECTIN; GLUCOSE; KANGEN KARYU; NITROGEN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; KIDNEY FIBROSIS; KIDNEY INJURY; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRESCRIPTION; PROTEIN EXPRESSION; RENAL PROTECTION; UPREGULATION;

ANIMALS; ANTIOXIDANTS; COLLAGEN TYPE IV; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOWN-REGULATION; DRUGS, CHINESE HERBAL; FATTY LIVER; FIBRONECTINS; FIBROSIS; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPERGLYCEMIA; KIDNEY; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, OBESE; RECEPTORS, IMMUNOLOGIC; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79958049192     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01299.x     Document Type: Article

References (50)

1. Ramasamy R, et al,. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005; 15: 16R-28R. (Pubitemid 41417992)
2. Ahmed N, Thornalley PJ,. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 2007; 9: 233-245. (Pubitemid 46502041)
3. Peyroux J, Sternberg M,. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol Biol (Paris) 2006; 54: 405-419. (Pubitemid 44468299)
4. Reddy VP, Beyaz A,. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov Today 2006; 11: 646-654.
5. Desai K, Wu L,. Methylglyoxal and advanced glycation endproducts: new therapeutic horizons? Recent Pat Cardiovasc Drug Discov 2007; 2: 89-99. (Pubitemid 46957320)
6. Hyogo H, et al,. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 1112-1119. (Pubitemid 47019866)
7. Iwamoto K, et al,. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol 2008; 43: 298-304. (Pubitemid 351650040)
8. Lal MA, et al,. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int 2002; 61: 2006-2014. (Pubitemid 34539318)
9. Yamagishi S, et al,. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells. Kidney Int 2003; 63: 464-473. (Pubitemid 36126793)
10. Takahashi M, et al,. Kangenkaryu prevents the decrease of cholinergic markers following the nucleus basalis magnocellularis lesion. Jpn J Pharmacol 1992; 60: 307-310. (Pubitemid 23009069)
11. Gao M, et al,. Studies on preventive effect of 'Kangenkaryu', Chinese herbal medicine, on stroke in SHR-SP. J Trad Med 2001; 18: 245-250.
12. Makino T, et al,. Effects of Kangen-karyu on coagulation system and platelet aggregation in mice. Biol Pharm Bull 2002; 25: 523-525. (Pubitemid 40036747)
13. Pu F, et al,. Ameliorating effects of Kangen-karyu on neuronal damage in rats subjected to repeated cerebral ischemia. J Nat Med 2010; 64: 167-174.
14. Zhao Q, et al,. Kangen-karyu improves memory deficit caused by aging through normalization of neuro-plasticity-related signaling system and VEGF system in the brain. J Ethnopharmacol 2010; 131: 377-385.
15. Yokozawa T, et al,. The protective role of Chinese prescription Kangen-karyu extract on diet-induced hypercholesterolemia in rats. Biol Pharm Bull 2006; 29: 760-765.
16. Yokozawa T, et al,. The protective role of Kangen-karyu against fructose-induced metabolic syndrome in a rat model. J Pharm Pharmacol 2007; 59: 1271-1278. (Pubitemid 47359907)
17. Kim HY, et al,. Beneficial effects of Chinese prescription Kangen-karyu on diabetes associated with hyperlipidemia, advanced glycation endproducts, and oxidative stress in streptozotocin-induced diabetic rats. J Ethnopharmacol 2009; 124: 263-269.
18. Yamabe N, et al,. Effect of Chinese prescription Kangen-karyu on lipid metabolism in type 2 diabetic db/db mice. J Ethnopharmacol 2010; 129: 299-305.
19. Momose T, et al,. Organic analysis. XLIV. A new deproteinizing agent for determination of blood sugar. Chem Pharm Bull 1963; 11: 968-972.
20. Stumvoll M, et al,. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346.
21. Poitout V, Robertson RP,. Glucolipotoxicity: fuel excess and β-cell dysfunction. Endocr Rev 2008; 29: 351-366. (Pubitemid 351679704)
22. Jéquier E,. Leptin signaling, adiposity, and energy balance. Ann NY Acad Sci 2002; 967: 379-388. (Pubitemid 34721923)
23. Sharma K, et al,. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003; 284: F1138-F1144. (Pubitemid 36578440)
24. Bierhaus A, et al,. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37: 586-600. (Pubitemid 28231153)
25. Greven WL, et al,. Mesangial accumulation of GA-pyridine, a novel glycolaldehyde-derived AGE, in human renal disease. Kidney Int 2005; 68: 595-602. (Pubitemid 43323114)
26. ε-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 1997; 324: 565-570.
27. Heidland A, et al,. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001; 38: S100-S106. (Pubitemid 32927622)
28. Nagai R, et al,. Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins. J Biol Chem 2002; 277: 48905-48912. (Pubitemid 35470860)
29. Bierhaus A, et al,. RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 2006; 7: 985-991. (Pubitemid 44756124)
30. Bedossa P, Paradis V,. Liver extracellular matrix in health and disease. J Pathol 2003; 200: 504-515. (Pubitemid 36818251)
31. Kanwar YS, et al,. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med 2008; 233: 4-11.
32. Verrecchia F, et al,. Transforming growth factor-β signaling through the Smad proteins: role in systemic sclerosis. Autoimmun Rev 2006; 5: 563-569. (Pubitemid 44488757)
33. Ziyadeh FN,. Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 2004; 15: S55-S57. (Pubitemid 38018457)
34. Qi W, et al,. Transcriptional regulation of the TGF-β1 promoter by androgen receptor. Biochem J 2008; 416: 453-462.
35. Li JH, et al,. Role of TGF-β signaling in extracellular matrix production under high glucose conditions. Kidney Int 2003; 63: 2010-2019. (Pubitemid 36605812)
36. Fukami K, et al,. AGEs activate mesangial TGF-β-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004; 66: 2137-2147. (Pubitemid 41115277)
37. Zhou G, et al,. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway. Am J Pathol 2004; 165: 2033-2043. (Pubitemid 39578381)
38. Li JH, et al,. Advanced glycation end products activate Smad signaling via TGF-β-dependent and -independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 2004; 18: 176-178.
39. Yang F, et al,. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-β-dependent and -independent Smad pathways. Hypertension 2009; 54: 877-884.
40. Ohta S, et al,. Studies on chemical protectors against radiation. XXX. Radioprotective substances of Cnidii Rhizome. Yakugaku Zasshi 1990; 110: 746-754. (Pubitemid 20383812)
41. Lee SC, et al,. Antioxidative constituents from Paeonia lactiflora. Arch Pharm Res 2005; 28: 775-783.
42. Zhou L, et al,. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2005; 45: 1345-1359. (Pubitemid 41643896)
43. Kim EO, et al,. Antioxidant properties and quantification of phenolic compounds from safflower (Carthamus tinctorius L.) seeds. Food Sci Biotechnol 2007; 16: 71-77.
44. Pandey MM, et al,. Saussurea costus: botanical, chemical and pharmacological review of an ayurvedic medicinal plant. J Ethnopharmacol 2007; 110: 379-390. (Pubitemid 46386372)
45. Yazdanparast R, Ardestani A,. In vitro antioxidant and free radical scavenging activity of Cyperus rotundus. J Med Food 2007; 10: 667-674.
46. Noh JS, et al,. Chinese prescription Kangen-karyu prevents dyslipidaemia and oxidative stress in mouse model of type 2 diabetes. J Pharm Pharmacol 2011; 63: 111-119.
47. Scott JA, King GL,. Oxidative stress and antioxidant treatment in diabetes. Ann NY Acad Sci 2004; 1031: 2004-2013.
48. Aragno M, et al,. Up-regulation of advanced glycated products receptors in the brain of diabetic rats is prevented by antioxidant treatment. Endocrinology 2005; 146: 5561-5567. (Pubitemid 41653072)
49. Lapolla A, et al,. Importance of measuring products of non-enzymatic glycation of proteins. Clin Sci 2005; 38: 103-115. (Pubitemid 40092452)
50. ε-(carboxymethyl)lysine- modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis. Clin Biochem 2006; 39: 39-45. (Pubitemid 43005268)